The trade price is 0.831 billion yuan! Cabio Biotech(Wuhan) disclosed the latest restructuring plan: it intends to reduce one trading counterpart and raise 0.269 billion yuan through a private placement.

① Both parties signed a performance commitment, promising that the Net income of Ouyi Biotech will not be less than 0.27 billion yuan in total for the fiscal years 2025, 2026, and 2027; ② The profits of Cabio Biotech(Wuhan) are expected to further increase. The company estimates that its revenue for the first three quarters of 2024 will rise from 0.387 billion yuan before the Trade to 0.655 billion yuan; the Net income attributable to the parent company will increase from 83.8902 million yuan to 0.113 billion yuan.

cls.cn19:47 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Publicly listed companies are scrambling to layout the Industry Chain of AI toys, which may lead to a surge.

① According to media reports, industry insiders believe that AI toys are one of the best landing scenarios for large models in the Hardware sector. Nowadays, not only are listed companies developing AI toy products, but many startup companies have also emerged and received tens of millions in financing. ② China Securities Co., Ltd. believes that the long payment cycle and high market growth of AI toys make them one of the best landing scenarios for current large models.

cls.cnJan 26 19:15 ET

Revenue has "returned to the 10 billion" target achieved. Three Squirrels Inc. expects a net profit increase of over 80% year-on-year last year | Interpretations.

① Three Squirrels Inc. expects to achieve revenue of 10.2 billion to 10.8 billion yuan in 2024, a year-on-year growth of 43.37% to 51.8%; it is expected to achieve net income of 0.4 billion to 0.42 billion yuan, a year-on-year increase of 81.99% to 91.09%; ② Following categories and channels, Three Squirrels Inc. has started to focus on building sub-brands.

cls.cnJan 21 08:39 ET

The trend of pet ownership is sweeping across the country and abroad. Petpal Pet Nutrition Technology expects a significant increase in profits in 2024 | Interpretations

① The scale of pet owners both domestically and internationally continues to expand, with an increasing number of dogs and cats globally. The profitability of related companies in Pet Food and supplies in China is generally improving; ② Petpal Pet Nutrition Technology's Jueyan brand of dog snacks has a solid market position, and Jueyan's main food has made some progress on the Douyin platform.

cls.cnJan 21 07:58 ET

Is the sales momentum of Douyin effective? Three Squirrels Inc. is expected to break 10 billion in revenue in 2024.

Channel transformation.

wallstreetcnJan 21 06:51 ET